{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:33:42Z","timestamp":1780047222395,"version":"3.53.1"},"reference-count":27,"publisher":"Georg Thieme Verlag KG","issue":"05","funder":[{"name":"Gonda Vascular Center and Vascular Medicine Research Funding, Mayo Clinic Rochester, MN, USA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients with cancer and venous thromboembolism (VTE) have higher complication rates of anticoagulation. However, studies supporting this data are relatively old reflecting the era of vitamin K inhibitors.<\/jats:p>\n                  <jats:p>To assess VTE recurrence, major bleeding, and clinically relevant non-major bleeding (CRNMB) in patients (March 1, 2013 to April 30, 2023) with cancer-associated VTE and patients without cancer, the prospective Mayo Clinic Thrombophilia Clinic Registry was analyzed.<\/jats:p>\n                  <jats:p>Over the study period, 4,711 patients with acute VTE were enrolled including 2,064 patients with cancer (mean age 62.5\u2009\u00b1\u200912.4, 46% female) and 2,647 patients without cancer (mean age 59.4\u2009\u00b1\u200916.0, 45% female). The most common cancers were gastrointestinal (n\u2009=\u2009423, 21%), pancreatic (n\u2009=\u2009287, 14%), and genitourinary (n\u2009=\u2009198, 10%). Direct oral anticoagulants were used in 1,339 (65%) cancer and in 1,952 (74%) non-cancer patients. Among cancer patients, 12-month Kaplan\u2013Meier probability of VTE recurrence was 2.4-fold greater (7.1% vs. 2.9%, p\u2009&lt;\u20090.001) compared with the non-cancer group, including higher recurrent leg deep vein thrombosis (3.0% vs. 1.4%; p\u2009=\u20090.002) and pulmonary embolism (3.5% vs. 1.0%, p\u2009&lt;\u20090.001). Patients with cancer also had 2.1-fold greater risk of major bleeding (6.3% vs. 3.0%; p\u2009&lt;\u20090.001) including bleeding from the gastrointestinal tract (3.0 vs. 1.4, p\u2009=\u20090.01) compared with patients without cancer. Clinically relevant non-major bleeding events were similar between the groups.<\/jats:p>\n                  <jats:p>In this large prospective registry of VTE management, patients with cancer had significantly higher rates of VTE recurrence and major bleeding compared with patients without cancer, yet the rate of complications are substantially smaller relative to historic values of a prior vitamin K antagonist era.<\/jats:p>","DOI":"10.1055\/a-2653-6161","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T22:41:21Z","timestamp":1753483281000},"page":"518-525","source":"Crossref","is-referenced-by-count":2,"title":["Venous Thromboembolism Outcomes Among Cancer and Non-cancer Patients Managed with Patient-centric Guideline-driven Protocol"],"prefix":"10.1055","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8858-1642","authenticated-orcid":false,"given":"Claire E.","family":"Cassianni","sequence":"additional","affiliation":[{"name":"Mayo Clinic Alix School of Medicine, Minnesota, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"McBane","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Gonda Vascular Center, Mayo Clinic, Minnesota, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle T.","family":"Vlazny","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Gonda Vascular Center, Mayo Clinic, Minnesota, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David O.","family":"Hodge","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, Florida, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana I.","family":"Casanegra","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Gonda Vascular Center, Mayo Clinic, Minnesota, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damon E.","family":"Houghton","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Gonda Vascular Center, Mayo Clinic, Minnesota, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waldemar E.","family":"Wysokinski","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Gonda Vascular Center, Mayo Clinic, Minnesota, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"issue":"06","key":"ref3","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archinte.160.6.809","article-title":"Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study","volume":"160","author":"J A Heit","year":"2000","journal-title":"Arch Intern Med"},{"issue":"03","key":"ref4","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"A A Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"25","key":"ref5","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","article-title":"Prognosis of cancers associated with venous thromboembolism","volume":"343","author":"H T S\u00f8rensen","year":"2000","journal-title":"N Engl J Med"},{"issue":"14","key":"ref6","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"F I Mulder","year":"2021","journal-title":"Blood"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"e1001275","DOI":"10.1371\/journal.pmed.1001275","article-title":"Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis","volume":"9","author":"F Horsted","year":"2012","journal-title":"PLoS Med"},{"issue":"17","key":"ref8","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1200\/JCO.2000.18.17.3078","article-title":"Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis","volume":"18","author":"B A Hutten","year":"2000","journal-title":"J Clin Oncol"},{"issue":"06","key":"ref9","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/archinte.160.6.769","article-title":"Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors","volume":"160","author":"P O Hansson","year":"2000","journal-title":"Arch Intern Med"},{"issue":"10","key":"ref10","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"P Prandoni","year":"2002","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.thromres.2022.11.005","article-title":"Influence of primary cancer site on clinical outcomes of anticoagulation for associated venous thromboembolism","volume":"221","author":"W E Wysokinski","year":"2023","journal-title":"Thromb Res"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1016\/j.mayocp.2021.04.026","article-title":"Bleeding in patients with gastrointestinal cancer compared with nongastrointestinal cancer treated with apixaban, rivaroxaban, or enoxaparin for acute venous thromboembolism","volume":"96","author":"D E Houghton","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"04","key":"ref13","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"S Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref14","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"S Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"24","key":"ref15","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"S Schulman","year":"2009","journal-title":"N Engl J Med"},{"issue":"09","key":"ref16","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"G Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"26","key":"ref17","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"R Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"issue":"14","key":"ref18","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"H R B\u00fcller","year":"2012","journal-title":"N Engl J Med"},{"issue":"15","key":"ref19","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"H R B\u00fcller","year":"2013","journal-title":"N Engl J Med"},{"issue":"06","key":"ref20","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"S M Stevens","year":"2021","journal-title":"Chest"},{"issue":"07","key":"ref21","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"G E Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"ref22","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"A M Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"ref23","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"G Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"22","key":"ref24","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial","volume":"329","author":"D Schrag","year":"2023","journal-title":"JAMA"},{"issue":"05","key":"ref25","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1055\/s-0042-1758835","article-title":"Survival implications of thrombus recurrence or bleeding in cancer patients receiving anticoagulation for venous thromboembolism treatment","volume":"123","author":"R D McBane Ii","year":"2023","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11239-020-02180-x","article-title":"Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE","volume":"50","author":"J I Weitz","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"11","key":"ref27","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1253\/circj.CJ-19-0515","article-title":"Cancer-associated venous thromboembolism in the real world\u2014from the COMMAND VTE registry","volume":"83","author":"J Sakamoto","year":"2019","journal-title":"Circ J"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.thromres.2023.12.016","article-title":"Cancer-associated venous thromboembolism in the direct oral anticoagulants era: insight from the COMMAND VTE Registry-2","volume":"234","author":"R Chatani","year":"2024","journal-title":"Thromb Res"},{"issue":"09","key":"ref29","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1111\/j.1538-7836.2006.02082.x","article-title":"Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry","volume":"4","author":"M Monreal","year":"2006","journal-title":"J Thromb Haemost"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2653-6161.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T22:37:03Z","timestamp":1776983823000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2653-6161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":27,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2026,4,23]]},"published-print":{"date-parts":[[2026,5]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2653-6161","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]}}}